Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma

Authors:

Abstract
Background: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation compared rituximab with observation post-ASCT. Materials and methods: Four hundred and seventy-six patients Results: At a median of 4 years’ follow-up from the second randomisation, there was a trend (P = 0.1) towards increased EFS for patients who received rituximab compared with observation. Conclusion: The type of induction therapy (ACVBP or ACE) did not significantly affect overall survival at a median 51 months’ follow-up.
Funding Information
  • Programme Hospitalier de Recherche Clinique (PHRC-AOM 98-117)

This publication has 31 references indexed in Scilit: